Absci (NASDAQ: ABSI) has recently received a number of price target changes and ratings updates:
- 6/15/2026 – Absci had its price target raised by Guggenheim from $10.00 to $15.00. They now have a “buy” rating on the stock.
- 6/4/2026 – Absci is now covered by Leerink Partners. They set an “outperform” rating and a $12.00 price target on the stock.
- 5/28/2026 – Absci is now covered by BTIG Research. They set a “buy” rating and a $9.00 price target on the stock.
- 5/28/2026 – Absci is now covered by BTIG Research. They set a “buy” rating and a $9.00 price target on the stock.
- 5/14/2026 – Absci was given a new $4.10 price target by Morgan Stanley.
- 5/8/2026 – Absci had its price target raised by Truist Financial Corporation from $9.00 to $11.00. They now have a “buy” rating on the stock.
- 4/20/2026 – Absci had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.
The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.
Featured Articles
- Five stocks we like better than Absci
- Draining the Tank: Big Oil Runs on Fumes
- Microsoft’s Xbox Problem Is Bigger Than a Console War
- Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
Receive News & Ratings for Absci Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
